0.1566
6.84%
-0.0115
Sonoma Pharmaceuticals Inc. stock is currently priced at $0.1566, with a 24-hour trading volume of 126.63K.
It has seen a -6.84% decreased in the last 24 hours and a +12.66% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.1691 pivot point. If it approaches the $0.1523 support level, significant changes may occur.
Sonoma Pharmaceuticals Inc. Stock (SNOA) Financials Data
Sonoma Pharmaceuticals Inc. (SNOA) Revenue 2024
SNOA reported a revenue (TTM) of $12.31 million for the quarter ending December 31, 2023, a -1.96% decline year-over-year.
Sonoma Pharmaceuticals Inc. (SNOA) Net Income 2024
SNOA net income (TTM) was -$5.08 million for the quarter ending December 31, 2023, a +25.21% increase year-over-year.
Sonoma Pharmaceuticals Inc. (SNOA) Cash Flow 2024
SNOA recorded a free cash flow (TTM) of -$5.20 million for the quarter ending December 31, 2023, a +0.88% increase year-over-year.
Sonoma Pharmaceuticals Inc. (SNOA) Earnings per Share 2024
SNOA earnings per share (TTM) was -$0.94 for the quarter ending December 31, 2023, a +59.31% growth year-over-year.
Sonoma Pharmaceuticals Inc. Stock (SNOA) Latest News
Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Benzinga
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga
About Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Cap:
|
Volume (24h):